Analyst
B. Riley Securities
Equibles does not estimate personal net worth.
Madison El-Saadi is recorded as Analyst at B. Riley Securities. Madison El-Saadi has spoken on 7 earnings calls across 6 companies, most recently for Capricor Therapeutics, Inc. on November 10, 2026. Those appearances were for Eton Pharmaceuticals, Inc. (ETON), Capricor Therapeutics, Inc. (CAPR), Axsome Therapeutics, Inc. (AXSM), Vanda Pharmaceuticals Inc. (VNDA), Arrowhead Pharmaceuticals, Inc. (ARWR) and 1 other company. The companies whose calls Madison El-Saadi spoke on are classified in the Healthcare sector.
“Would you expect any of the cardiomyopathy subgroup data, the LGE results? To appear anywhere in a potential label, even though the focus now is on upper limb, or do you think this really even matters in terms of the potential launch?”
“Is this something you think would have efficacy on top of a D2 antagonist or even a muscarinic compound without increasing the movement disorder risk, or is this something that the team envisions as ultimately being a potential first-line therapy?”
“So it sounds like much of the 2QB here came from Hemangiol. How much of the $25 million raised guide is Hemangiol versus everything else?”
“A couple from us, maybe sticking with the Narius campaign, what exactly does the personal promotion start? How many reps are we talking? Does that spin sit inside the OpEx moderation you guided to relatedly?”
“Maybe one on Triggs and just specifically as it relates to sort of your expectations around the commercial opportunity. You know, with your data out there now, the Ionis launch is sort of underway.”
B. Riley Securities
Analyst
Source not stated
Drug Manufacturers - Specialty & Generic · Healthcare
CMPS
Medical Care Facilities · Healthcare
